





AMENDMENTS

In the Claims:

1. (Canceled).
2. (Canceled).
3. (Currently amended) The compound or compounds according to claim 34, selected from the group consisting of the compounds of formulae Ia, Ib, Ic and Id,







wherein

R⁷, R⁸, R⁹, R¹⁰, X, Y, p and q and are as defined in claim 34,
or tautomeric forms thereof, ~~pharmaceutically acceptable derivatives,~~
~~solvates,~~ salts and stereoisomers thereof or mixtures thereof in all ratios.



4. (Canceled).
5. (Currently amended) The compound or compounds according to claim 34, having formula A-CO-NH-B, wherein A- and -B are selected from the group consisting of

	A-	-B
(1)		
(2)		
(3)		



(4)





(5)





(6)





(7)





(8)





(9)





(10)





(11)





(12)





(13)





(14)





(15)





(16)





(17)





(18)





(19)





(20)





(21)





(22)

















(23)





(24)








(32)




(33)




(34)





(35)





(36)





(37)





(38)





(39)





(40)




(41)





(42)





(43)

















(44)




(45)








(53)





(54)





(55)





(56)





(57)

















(58)





(59)









(67)





(68)





(69)





(70)





(71)





(72)





(73)





(74)





(75)





(76)





(77)





(78)





(79)





(80)





(81)





(82)





(83)





(84)





(85)





(86)





(87)





(88)





(89)





(90)





(91)





(92)





(93)





(94)





(95)





(96)





(97)





(98)





(99)





(100)





(101)





(102)





(103)





(104)





(105)





(106)





(107)





(108)





(109)





(110)





(111)





(112)





(113)





(114)





(115)





(116)





(117)





(118)

















(119)





(120)





(128)




or tautomeric forms, ~~pharmaceutically acceptable derivatives, solvates, salts, stereoisomers or mixtures thereof in all ratios.~~

6. (Canceled).
7. (Canceled).
8. (Canceled).
9. (Currently amended) A pharmaceutical composition, comprising one or more of the compound or compounds according to claim 34, or tautomeric forms, ~~pharmaceutically acceptable derivatives, solvates, salts, stereoisomers or mixtures thereof in all ratios, in a pharmaceutical composition.~~
10. (Previously presented) The pharmaceutical composition according to claim 9, characterized in that it contains one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients.
11. (Currently amended) A process for the manufacture of a pharmaceutical composition, comprising that one or more of the compound or compounds according to claim 34, or tautomeric forms, ~~pharmaceutically acceptable derivatives, solvates, salts, stereoisomers or mixtures thereof in all ratios, and one or more compound or compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compound or compounds according to claim 34, is processed by mechanical means into a pharmaceutical composition that is suitable as dosage form for application and/or administration to a patient.~~

12. (Withdrawn/Previously presented) A method comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition according to claim 9.
13. (Withdrawn/Previously presented) A method comprising administering to a patient an effective amount of the pharmaceutical composition according to claim 9 for the treatment and/or prophylaxis of a disorder or disorders.
14. (Canceled).
15. (Withdrawn) The method of claim 13, characterized in that the disorder or disorders are caused, mediated and/or propagated by kinases selected from the group consisting of raf-kinases and VEGFR kinases.
16. (Withdrawn) The method of claim 13, characterized in that the disorder or disorders are selected from the group consisting of hyperproliferative and nonhyperproliferative disorders.
17. (Withdrawn) The method of claim 13, characterized in that the disorder or disorders is cancer.
18. (Withdrawn) The method of claim 13, characterized in that the disorder or disorders is noncancerous.
19. (Withdrawn) The method of claim 18, characterized in that the noncancerous disorder or disorders are selected from the group consisting of infections, psoriasis, arthritis, inflammation, endometriosis, scarring, benign prostatic hyperplasia, immunological disease, autoimmune disease and immunodeficiency disease.

20. (Withdrawn) The method of claim 17, characterized in that the cancer is selected from the group consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.
21. (Withdrawn) The method of claim 13, characterized in that the disorder or disorders are selected from the group consisting of arthritis, restenosis; fibrotic disorders; mesangial cell proliferative disorders, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection, glomerulopathies, metabolic disorders, inflammation and neurodegenerative disease.
22. (Withdrawn) The method of claim 13, characterized in that the disorder or disorders are selected from the group consisting of rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, renal disease and angiogenesis disorders.
23. (Withdrawn) A method of treatment comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition according to claim 9, as a kinase inhibitor.
24. (Withdrawn) The method of claim 23, characterized in that the kinase is one or more raf-kinases, selected from the group consisting of A-Raf, B-Raf and Raf-1.
25. (Canceled).
26. (Canceled).

27. (Canceled).
28. (Withdrawn) The method of claim 17, characterized in that the disorder or disorders is cancerous cell growth mediated by one or more kinases.
29. (Withdrawn/Currently amended) A method for producing the compound or compounds of claim 34, or tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, or stereoisomers thereof, comprising that
- a) a compound of formula II




wherein

L^1 is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and R^6 , R^8 , p and Y are as defined in claim 34,

is reacted

- b) with a compound of formula III,




wherein

L^2 is H or a metal ion, and R^7 , R^9 , q , X , Ar^2 , R^{10} and r are as defined in claim 34,

and optionally

- c) isolating and/or treating the compound or compounds of claim 34, obtained by said reaction with an acid, to obtain the salt thereof.


30. (Withdrawn) A compound or compounds of formula II,



wherein

L^1 is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and R^6 , R^8 , p and Y are as defined in claim 1.

31. (Withdrawn) A compound or compounds of formula III,




wherein

L^2 is H or a metal ion, and R^7 , R^9 , q , X , Ar^2 , R^{10} and r are as defined in claim 1.

32. (Canceled).

33. (Canceled).

34. (Currently amended) A compound or compounds of formula I



wherein

Ar^2 is pyridinyl or pyrimidyl,

R^6 , R^7 independently from one another, are H or unbranched or branched alkyl comprising 1 to 6 carbon atoms, optionally substituted by one or more Hal atoms,

R^8 , R^9 independently from one another, are selected from the group consisting of A, H, Hal and unbranched or branched alkyl comprising 1 to 6 carbon atoms, optionally substituted by one or more Hal atoms,

A is selected from the group consisting of alkyl, alkenyl, cycloalkyl, alkylene cycloalkyl, alkoxy and alkoxyalkyl,

R^{10} is selected from the group consisting of H, alkyl comprising 1 to 4 carbon

atoms and $(CH_2)_nCONR^{11}R^{12}$,

R^{11}, R^{12} independently from one another, are selected from the group consisting of H, Hal and branched or unbranched alkyl comprising 1 to 6 carbon atoms, optionally substituted by one or more Hal atoms,

n is 0, 1, 2, 3, 4, or 5,

X is O or CH_2 ,

Y is O,

p is 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4,

r is 0, 1, 2 or 3,

and

Hal is selected from the group consisting of F, Cl, Br and I

or tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, stereoisomers or mixtures thereof in all ratios.

35. (Currently amended) The compound or compounds according to claim 34,
wherein

Ar^2 is pyridinyl,

R^6 , R^7 independently from one another, are H or are selected from the group consisting of methyl, ethyl, trifluoro methyl, pentafluoro ethyl, isopropyl, and tert.-butyl,

R^8 , R^9 independently from one another, are H or hal or are selected from the group consisting of methyl, ethyl, trifluoro methyl, pentafluoro ethyl, isopropyl, and tert.-butyl, and,

X is O, and

hal is selected from the group consisting of F, Cl and Br,

or tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, stereoisomers or mixtures thereof in all ratios.